A Treatment for Paroxysmal Nocturnal Hemoglobinuria Was Accepted for Priority Review
<a href="https://pixabay.com/users/Clker-Free-Vector-Images/">Clker-Free-Vector-Images</a> / Pixabay

A Treatment for Paroxysmal Nocturnal Hemoglobinuria Was Accepted for Priority Review

According to a story from Morningstar, the company Alexion Pharmaceuticals recently announced that the U.S. Food and Drug Administration (FDA) has agreed to review their Biologics Licensing Application for their…

Continue Reading
Takeda and Ovid Have Provided an Update on the Clinical Development Program for an Investigational Anti-Epileptic Drug
<a href="https://pixabay.com/users/stevepb/">stevepb</a> / Pixabay

Takeda and Ovid Have Provided an Update on the Clinical Development Program for an Investigational Anti-Epileptic Drug

  Takeda Pharmaceutical Company Limited and Ovid Therapeutics have released an overview of the clinical development program for TAK-935/OV935, an investigational drug that is being developed as a potential anti-epileptic…

Continue Reading

What are your thoughts on being a rare disease advocate? Share your stories, thoughts, and hopes with the Patient Worthy community!

Close Menu